Comparison of efficacy and toxicity of FC and FCR regimens in primary B-cell chronic lymphocytic leukemia: a retrospective study

Ye. А. Stadnik; Стадник Е. А.; Ye. А. Nikitin; Никитин Е. А.; B. V. Biderman; Бидерман Б. В.; G. N. Salogub; Салогуб Г. Н.; Yu. Yu. Lorie; Лорие Ю. Ю.; N. N. Tsyba; Цыба Н. Н.; Yu. A. Alexeeva; Aлексеева Ю. А.; V. A. Doronin; Доронин В. А.; V. N. Mashuk; Мащук В. Н.; R. I. Vabishevich; Вабищевич Р. И.; A. L. Melikyan; Меликян А. Л.; T. I. Kolosheinova; Колошейнова Т. И.; L. Yu. Kolosova; Колосова Л. Ю.; A. B. Sudarikov; Судариков А. Б.; L. G. Kovaleva; Ковалева Л. Г.; A. Yu. Zaritsky; Зарицкий А. Ю.

doi:10.17650/1818-8346-2008-0-1-2-39-46

Comparison of efficacy and toxicity of FC and FCR regimens in primary B-cell chronic lymphocytic leukemia: a retrospective study

Authors: Stadnik Y.А.¹, Nikitin Y.А.², Biderman B.V.², Salogub G.N.¹, Lorie Y.Y.², Tsyba N.N.², Alexeeva Y.A.¹, Doronin V.A.³, Mashuk V.N.⁴, Vabishevich R.I.⁵, Melikyan A.L.², Kolosheinova T.I.², Kolosova L.Y.², Sudarikov A.B.², Kovaleva L.G.², Zaritsky A.Y.⁵
Affiliations:
1. Городская клиническая больница №31
2. ГУ «Гематологический научный центр» РАМН
3. Центральная клиническая больница №2 Министерства путей сообщения
4. Краснодарский краевой онкодиспансер
5. Федеральный центр крови, сердца и эндокринологии им. акад. В.А. Алмазова
Issue: No 1-2 (2008)
Pages: 39-46
Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
Published: 23.05.2008
URL: https://oncohematology.abvpress.ru/ongm/article/view/679
DOI: https://doi.org/10.17650/1818-8346-2008-0-1-2-39-46
ID: 679

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Preclinical studies showed synergic anti-tumor activity of Rituximab and Fludarabin. Comparison of efficacy of FC with FCR regimens administered in first line therapy and their influence on disease-free and overall survival in patients with B-cell lymphocytic leukemia were the main goals of this retrospective study. It has been demonstrated that inclusion of Rituximab into the FC regimen improves outcome of patients with B-cell lymphocytic leukemia without significant increase of toxicity.